- Home
- SKYA vs TLPH Comparison
SKYA vs TLPH Comparison
Compare SKYA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYA | TLPH |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.7M | 70.3M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SKYA | TLPH |
|---|---|---|
| Price | $2.79 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | ★ 1.8M | 127.3K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $204,120.00 | ★ $2,151,000.00 |
| Revenue This Year | $35,369.33 | N/A |
| Revenue Next Year | $9.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $0.69 |
| 52 Week High | $2.83 | $11.90 |
Technical Indicators
Market Signals| Indicator | SKYA | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 75.68 | 40.64 |
| Support Level | $1.60 | $1.03 |
| Resistance Level | N/A | $1.13 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 98.37 | 34.38 |
Price Performance
Historical ComparisonAbout SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.